Pharm Exec Podcast
Pharmaceutical Executive Daily: Why DSCSA Compliance is Only The Beginning
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:02:37
- Mas informaciones
Informações:
Sinopsis
In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Johnson & Johnson’s Simponi for pediatric ulcerative colitis, why DSCSA compliance is only the beginning of pharma supply chain modernization, and the agency’s approval of Jascayd for idiopathic pulmonary fibrosis.
